If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the company. But how likely is that? Let's find out how things might evolve for ...

Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...

Recursion Pharmaceuticals jumped by 16.44 percent on Wednesday to close at $6.09 apiece as investors repositioned portfolios ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...